 |
PDBsum entry 2m0p
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Lipid binding protein
|
PDB id
|
|
|
|
2m0p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
J Biol Chem
288:4424-4435
(2013)
|
|
PubMed id:
|
|
|
|
|
| |
|
Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the nmr structure of the 10th complement type repeat domain alone and in complex with gentamicin.
|
|
R.Dagil,
C.O'Shea,
A.Nykjær,
A.M.Bonvin,
B.B.Kragelund.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Gentamicin is an aminoglycoside widely used in treatments of, in particular,
enterococcal, mycobacterial, and severe Gram-negative bacterial infections.
Large doses of gentamicin cause nephrotoxicity and ototoxicity, entering the
cell via the receptor megalin. Until now, no structural information has been
available to describe the interaction with gentamicin in atomic detail, and
neither have any three-dimensional structures of domains from the human megalin
receptor been solved. To address this gap in our knowledge, we have solved the
NMR structure of the 10th complement type repeat of human megalin and
investigated its interaction with gentamicin. Using NMR titration data in
HADDOCK, we have generated a three-dimensional model describing the complex
between megalin and gentamicin. Gentamicin binds to megalin with low affinity
and exploits the common ligand binding motif previously described (Jensen, G.
A., Andersen, O. M., Bonvin, A. M., Bjerrum-Bohr, I., Etzerodt, M., Thogersen,
H. C., O'Shea, C., Poulsen, F. M., and Kragelund, B. B. (2006) J. Mol. Biol.
362, 700-716) utilizing the indole side chain of Trp-1126 and the negatively
charged residues Asp-1129, Asp-1131, and Asp-1133. Binding to megalin is highly
similar to gentamicin binding to calreticulin. We discuss the impact of this
novel insight for the future structure-based design of gentamicin antagonists.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |